PERSONALIZED MEDICINE BIOMARKERS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Personalized Medicine Biomarkers Market, By Type (Genetic Biomarkers, Protein Biomarkers, and Metabolite Biomarkers), By Application (Oncology, Neurology, Diabetes, Autoimmune Diseases, Cardiology, and Others), By End User (Hospitals, Diagnostic Laboratories, and Research Institutions), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

In August 2024, Paige, a digital pathology platform, launched OmniScreen, an AI-driven biomarker module that analyzes over 505 genes and identifies 1,228 molecular biomarkers from standard H&E-stained digital pathology slides
In August 2024, Illumina, Inc., a biotechnology company, announced U.S. FDA (Food and Drug Administration) approval for its TruSight Oncology Comprehensive test, which profiles over 500 genes to identify immuno-oncology and clinically actionable biomarkers, supporting targeted therapies and clinical trial participation
On June 1, 2024, Sapience Therapeutics, a biotechnology company, presented positive clinical and biomarker data from its Phase 2 ST101 study in glioblastoma (GBM) at the ASCO 2024 Annual Meeting. The data showed durable responses across three patient cohorts, including both recurrent and newly diagnosed GBM cases.
In February 2022, the U.S. FDA, Food and Drug Administration approved FoundationOne CDx as a companion diagnostic for Keytruda, enabling the identification of patients with microsatellite instability-high solid tumors